Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer
Korean Journal of Pathology
;
: 435-440, 2009.
Article
in Korean
| WPRIM
| ID: wpr-123699
ABSTRACT
BACKGROUND:
Taxane-platinum combinations are often used as first-line treatments for patients with advanced non-small cell lung cancer (NSCLC). Response to chemotherapy for these patients is still poor. The aim of our study was to investigate, for this disease, whether KRAS and Tau proteins affect responses to taxane-platinum combinations.METHODS:
Expression of KRAS and Tau was examined immunohistochemically in 71 tumor samples obtained from patients with stage IIIB or IV NSCLC prior to combination therapy. Expression was correlated with tumor responses.RESULTS:
The response rate was 55% (39 of 71). KRAS and Tau were expressed in seven (10%) and 31 (44%) patients, respectively. All seven KRAS-positive patients were non-responders (p=0.014). Among Tau-positive patients, 35% (11 of 31) responded to therapy, whereas a partial response was observed in 70% (28 of 40) of Tau-negatives (p=0.045). Two were positive for both, and they were non-responders. In patients negative for both, the response rate was 71% (25 of 35) (p=0.012).CONCLUSIONS:
Expression of KRAS and Tau are significantly correlated with poor responses to this combination therapy in advanced NSCLC patients, and may be a useful marker for chemoresistance.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Proto-Oncogene Proteins
/
Tau Proteins
/
Carcinoma, Non-Small-Cell Lung
/
Ras Proteins
/
Lung
/
Lung Neoplasms
Type of study:
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Pathology
Year:
2009
Type:
Article
Similar
MEDLINE
...
LILACS
LIS